sCD14 in dialysis patients were not influenced by the dialysis session or the type of hemodialysis membrane. There was no bacterial growth, and < 0.5 pg/ml endotoxin resulted with two filters. The medians for bacterial counts and endotoxin with a filter were 0.3 CFU/ml and 3.6 pg/ml, respectively, and 3.2 CFU/ml and 6.9 pg/ml without a filter, respectively. In group 1, with ultrafilters, the sCD14 level was significantly lower than with regular dialysate, group 3 ( fig. 1) . The normal value for serum sCD14 has been reported as 1-6 µg/ml [6] . The source of sCD14 has yet to be determined. The increase in sCD14 levels is considered the consequence of the activation of cells expressing CD 14. Labeta et al. [7] demonstrated the release of two different soluble forms of CD14 (α, 48 kD, and ß, 56 kD). Moreover, sCD14 may also originate from nonmyeloid cells [8] . The addition of LPS and TNF-α led to an increase in sCD14 levels, IFN-γ and IL-4 down-regulate sCD14 release in monocytes and macrophages. LPS-sCD14 complexes interact with an as yet unknown receptor on the endothelial surfaces. sCD14 mediates activation of transcription factor NF-κ B by LPS in human endothelial cells independent of LBP [9] . sCD 14 is involved in the induction by LPS of HUVEC IL-6 and IL-8 biosynthesis, as well as ICAM-1 and VCAM-1 expression [10] . It has been shown that high concentrations of LPS down-modulated the expression of CD 14 on monocytes through a shedding process. CD 14 was partially down-modulated in monocytes during PAN or cuprophane dialysis. sCD14 was increased in CAPD and hemodialysis patients compared to controls. We suggested that up-regulated expression of inflammatory cytokines and adhesion molecules promotes activation and infiltration of macrophages causing dialysis-related amyloidosis in maintenance hemodialysis patients [11] . The changes in the sCD 14 levels may reflect the monocyte activation because of a slight influence by dia-lyzer clearance. The use of sterile dialysates may decrease the monocyte activation of KAHGEH E-Mail karger@karger.ch Fax + 4161306 12 34 http://www. karger. ch © 1996 S. Karger AG, Base! 0028-2766/96/0733-0493$10.00/0 I Controls CAPD Group 1 with 2 filters n=23 Group 2 Group 3 with without 1 filter filter n=26 n=54 n=9 π=10 long-term hemodialysis. The limulus amebo-cyte lysate assay only detects species of LPS with an apparent molecular weight above 8,000 D [12] . We have demonstrated that the LPS in the dialysate had a low molecular weight of approximately 4,000 D and that LPS may transfer across the dialysis membrane [13] .
These results suggest that bacterial contamination of the dialysate increases mono-cytic sCD14 in dialysis patients. Serum levels of sCD14 can be diminished by the use of ultrafiltered dialysate. The sCD14 level may be a marker for the state of monocyte activation by LPS. Fig. 1 . Serum sCD14 levels in µg/ml, in the control, CAPD and HD groups. Results are expressed as mean ± SD. * p < 0.01 versus controls. The difference between group 1 ‚ with ultrafilters, and group 3, without ultrafilters, was significant (p < 0.01).
